Stocks in Focus on December 3: Ujjivan Small Fin bank, CG Consumer to RBL Bank; here are the 5 Newsmakers of the Day
CG Consumer: Advent International, a private equity firm, and Temasek, Singapore state investment company, have decided to sell 26% shares of the company through a block deal. The floor price has been fixed at Rs 240 per shares.
Key equity barometers ended almost flat after a volatile session on Monday, December 2, 2019, as gains in Bharti Airtel, JSW Steel, Reliance Industries Kotak Bank and Axis Bank were offset by losses in Yes Bank, Eicher Motors, Bharti Infratel, Bajaj Finance, ONGC and BPCL. Investor risk appetite remained low due to weak core sector output, lower than expected auto sales and GDP data raised concerns over the health of the domestic economy. But certain stocks came in news after the market was closed for trading purposes. These stocks can have an impact on the indices when it reopens for trading purposes on Tuesday, December 3, 2019.
Here is a list of five such stocks:
Ujjivan Small Finance Bank: The initial public offering (IPO) of Ujjivan Small Finance Bank (USFB) has been subscribed 1.62 times on December 2, the first day of bidding. The public issue comprises a fresh issue of Rs 750 crore, will close on December 4, 2019. The company has fixed a price band at Rs 36-37 per share for the IPO.
Vodafone Idea and Airtel: The new prepaid tariff plans of Vodafone Idea and Airtel will become applicable from today, December 3, 2019. The tariff is likely to be raised by 20-40%.
CG Consumer: Advent International, a private equity firm, and Temasek, Singapore state investment company, have decided to sell 26% shares of the company through a block deal. The floor price has been fixed at Rs 240 per shares.
RBL Bank: The private lender on Monday announced its plan to raise Rs2,025 crore by issuing equity shares through qualified institutional placement offering (QIP) route. Floor Price set at Rs 352.57 each as a floor price for the share sale.
Watch Zee Business Live TV below:
Biocon: Biocon and Mylan have launch Trastuzumab biosimilar Ogivri in US market. Ogivri, a biosimilar to Herceptin, has been co-developed by Biocon Biologics and Mylan and will be available in 150 mg and 420 mg strengths. The drug used in treatment for breast and stomach cancer.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
09:33 AM IST